After hearing presentations from 43 speakers at the Fourth Global NASH Congress, the Surfing the NASH Tsunami team convenes one more time to consider how treatment paradigms and guidelines are likely to evolve over the next five years. This discussion focuses on general themes and differences between the US and UK market evolution. The conversation includes controversy and probing questions, all with laughter and camaraderie.
TOPICS: Diagnostics, Drugs, Patients, Policy and Perspectives Tags: aldafermin, cirrhosis, FGF-21, FibroScan, Fibrosis Level 3, Fibrosis Level 4, Genfit, NAFLD, NASH, NGM Biopharmaceuticals, Precision medicine, NICE, cost-effectiveness, guidelines, PMPLA3, resmetirom
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast
